Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alchemia has signed an agreement with Dr Reddy’s for marketing Fondaparinux sodium for injectionin in all territories outside of North America. The agreement does not in any way alter the existing arrangements between the companies for the manufacture and North American marketing of Fondaparinux.
Subscribe to our email newsletter
Fondaparinux is a generic version of GlaxoSmithKline’s Arixtra. Fondaparinux is an anticoagulant (blood thinner) used for the treatment and prevention of deep vein thrombosis (DVTs).
As per the terms of the agreement, Alchemia is expected to receive a royalty on sales at an agreed proportion from Dr Reddy’s, while Dr Reddy’s is expected to have the option to market the drug itself or enter into agreements with third parties.
Pete Smith, CEO of Alchemia, said: “Dr Reddy’s has the experience of directly marketing generic drugs in a large number of countries and supplying API to numerous other pharmaceutical and generic companies.
“Whilst Alchemia has been approached by a number of companies interested in marketing Fondaparinux, it would be inefficient for us to identify and enter into multiple agreements in the markets where we have no experience.”